糖尿病足介入综合诊治临床指南(第五版)
|
摘要
糖尿病足是糖尿病最常见的并发症之一,具有发病率高、致残率高、致死率高和治愈率低的特点,严重影响国人身体健康和生活质量,对其却一直没有统一的规范治疗方法。2015年,中国糖尿病足细胞与介入治疗技术联盟制定糖尿病足介入综合诊治临床指南(第一版),填补了国内糖尿病足治疗规范的空白,对提高我国救治水平起到重要作用。近10年来,随着诊断标准和治疗方式更新及国内外相关研究不断深入,联盟组织国内89家单位在第四版基础上进行新的修订。现颁布第五版指南,以进一步规范我国糖尿病足临床诊治。
Diabetic foot is one of the most common complications of diabetes mellitus, and it has the characteristics of high incidence, high disability rate, high mortality and low cure rate, which has seriously affected the health and quality of life of Chinese people. However, so far there has been no uniform and standardized therapeutic method for diabetic foot. In 2015, China Diabetic Cellular and Interventional Therapy Technology Alliance for Diabetic Foot formulated the 《Clinical Guidelines for Comprehensive Diagnosis and Treatment of Diabetic Foot(first edition)》, which filled in the blank of diabetic foot treatment standard in China and has played an important role in improving the treatment level of diabetic foot in China.In the past 10 years, because of the renewal of diagnostic criteria and treatment methods, as well as the deepening of related researches both at home and abroad, the Alliance for Diabetic Foot organizes 89 medical centers in China to make a revision for the 《Clinical Guidelines for Comprehensive Diagnosis and Treatment of Diabetic Foot》 on the basis of its fourth edition. Hereby, the fifth edition guidelines is issued so as to further standardize the clinical diagnosis and treatment of diabetic foot in China.
Diabetic foot is one of the most common complications of diabetes mellitus, and it has the characteristics of high incidence, high disability rate, high mortality and low cure rate, which has seriously affected the health and quality of life of Chinese people. However, so far there has been no uniform and standardized therapeutic method for diabetic foot. In 2015, China Diabetic Cellular and Interventional Therapy Technology Alliance for Diabetic Foot formulated the 《Clinical Guidelines for Comprehensive Diagnosis and Treatment of Diabetic Foot(first edition)》, which filled in the blank of diabetic foot treatment standard in China and has played an important role in improving the treatment level of diabetic foot in China.In the past 10 years, because of the renewal of diagnostic criteria and treatment methods, as well as the deepening of related researches both at home and abroad, the Alliance for Diabetic Foot organizes 89 medical centers in China to make a revision for the 《Clinical Guidelines for Comprehensive Diagnosis and Treatment of Diabetic Foot》 on the basis of its fourth edition. Hereby, the fifth edition guidelines is issued so as to further standardize the clinical diagnosis and treatment of diabetic foot in China.
引文
[1] Hingorani A, La Muraglia GM, Henke P, et al. The management of diabetic foot:a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine[J]. J Vasc Surg, 2016, 63(2 Suppl):3S-21S.
[2]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010年版)[J].中国医学前沿杂志·电子版, 2011, 3:54-109.
[3]陈欣蕾,彭玮琪,欧青,等. 2017年糖尿病重要临床进展回顾[J].中国实用内科杂志, 2018, 38:354-357.
[4]中国糖尿病足细胞与介入治疗技术联盟.糖尿病足介入综合诊治临床指南[J].中国介入影像与治疗学, 2018, 15:3-12.
[5]国际血管联盟中国分会糖尿病足专业委员会.糖尿病足诊治指南[J].介入放射学杂志, 2013, 22:705-708.
[6] Catterall RC, Martin MM, Oakley W. Aetiology and management of lesions of the feet in diabetesp[J]. Br Med J, 1956, 2:953-957.
[7] Catterall WA, Pedersen PL. Adenosine triphosphatase from rat liver mitochondria.Ⅱ. Interaction with adenosine diphosphate[J]. J Biol Chem, 1972, 247:7969-7976.
[8] Kalish J, Hamdan A. Management of diabetic foot problem[J]. J Vasc Surg, 2010, 51:476-486.
[9] Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis:glycosylated hemoglobin and cardiovascular disease in diabetes mellitus[J]. Ann Intern Med, 2004, 141:421-431.
[10] Gershater MA, Londahl M, Nyberg P, et al. Complexity of factors related to outcome of neuropathic and neuroischaemic/ischaemic diabetic foot ulcers:a cohort study[J]. Diabetologia,2009, 52:398-407.
[11] Apelqvist J. The foot in perspective[J]. Diabetes Metab Res Rev, 2008, 24(Suppl 1):S110-S115.
[12] Apelqvist J, Bakker K, van Houtum WH, et al. International consensus and practical guidelines on the management and the prevention of the diabetic foot. International Working Group on the Diabetic Foot[J]. Diabetes Metab Res Rev, 2000, 16(Suppl 1):S84-S92.
[13] Jeffcoate WJ, Chipchase SY, Ince P, et al. Assessing the outcome of the management of diabetic foot ulcers using ulcerrelated and person-related measures[J]. Diabetes Care, 2006,29:1784-1787.
[14] Clairotte C, Retout S, Potier L, et al. Automated ankle-brachial pressure index measurement by clinical staff for peripheral arterial disease diagnosis in nondiabetic and diabetic patients[J].Diabetes Care, 2009, 32:1231-1236.
[15] Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease(TASCⅡ)[J]. Eur J Vasc Endovasc Surg, 2007, 33(Suppl 1):S1-S75.
[16] European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of HypertensionEuropean Society of Cardiology guidelines for the management of arterial hypertension[J]. J Hypertens, 2003, 21:1011-1153.
[17] American Diabetes Association. Standards of medical care in diabetes-2006[J]. Diabetes Care, 2006, 29(Suppl 1):S4-S42.
[18] Lepantalo M, Apelqvist J, Setacci C, et al. ChapterⅤ:diabetic foot[J]. Eur J Vasc Endovasc Surg, 2011, 42(Suppl 2):S60-S74.
[19] Elraiyah T, Tsapas A, Prutsky G, et al. A systematic review and meta-analysis of adjunctive therapies in diabetic foot ulcers[J]. J Vasc Surg, 2016, 63(2 Suppl):46S.el-2-58S.el-2.
[20] Meloni M, Izzo V, Vainieri E, et al. Management of negative pressure wound therapy in the treatment of diabetic foot ulcers[J]. World J Orthop, 2015, 6:387-393.
[21] Shi R, Jin Y, Cao C, et al. Localization of human adiposederived stem cells and their effect in repair of diabetic foot ulcers in rats[J]. Stem Cell Res Ther, 2016, 7:155.
[22] Lu C, Zhang X, Zhang D, et al. Short time tripterine treatment enhances endothelial progenitor cell function via heat shock protein 32[J]. J Cell Physiol, 2015, 230:1139-1147.
[23] Lu C, Yu X, Zuo K, et al. Tripterine treatment improves endothelial progenitor cell function via integrin-linked kinase[J].Cell Physiol Biochem, 2015, 37:1089-1103.
[24] Zuo K, Li M, Zhang X, et al. MiR-21 suppresses endothelial progenitor cell proliferation by activating the TGFβsignaling pathway via downregulation of WWP1[J]. Int J Clin Exp Pathol,2015, 8:414-422.
[25] Zhang X, Lian W, Lou W, et al. Transcatheter arterial infusion of autologous CD133+cells for diabetic peripheral artery disease[J]. Stem Cells Int, 2016, 2016:6925357.
[26] Zhao WN, Xu SQ, Liang JF, et al. Endothelial progenitor cells from human fetal aorta cure diabetic foot in a rat model[J].Metabolism, 2016, 65:1755-1767.
[27] Wu Q, Chen B, Liang Z. Mesenchymal stem cells as a prospective therapy for the diabetic foot[J]. Stem Cells Int, 2016,2106:4612167.
[28] Hinchliffe RJ, Brownrigg JR, Apelqvist J, et al. IWGDF guidance on the diagnosis, prognosis and management of peripheral artery disease in patients with foot ulcers in diabetes[J]. Diabetes Metab Res Rev, 2016, 32(Suppl 1):37-44.
[29] Asadi MR, Torkaman G, Hedayati M, et al. Angiogenic effects of low-intensity cathodal direct current on ischemic diabetic foot ulcers:a randomized controlled trial[J]. Diabetes Res Clin Pract,2017, 127:147-155.
[30] Chatwin KE, Abbott CA, Reddy PN, et al. A foreign body through the shoe of a person with diabetic peripheral neuropathy alters contralateral biomechanics:captured through innovative plantar pressure technology[J]. Int J Low Extrem Wounds, 2018,17:125-129.
[31] Crisologo PA, Lavery LA. Remote home monitoring to identify and prevent diabetic foot ulceration[J]. Ann Transl Med, 2017,5:430.
[2]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010年版)[J].中国医学前沿杂志·电子版, 2011, 3:54-109.
[3]陈欣蕾,彭玮琪,欧青,等. 2017年糖尿病重要临床进展回顾[J].中国实用内科杂志, 2018, 38:354-357.
[4]中国糖尿病足细胞与介入治疗技术联盟.糖尿病足介入综合诊治临床指南[J].中国介入影像与治疗学, 2018, 15:3-12.
[5]国际血管联盟中国分会糖尿病足专业委员会.糖尿病足诊治指南[J].介入放射学杂志, 2013, 22:705-708.
[6] Catterall RC, Martin MM, Oakley W. Aetiology and management of lesions of the feet in diabetesp[J]. Br Med J, 1956, 2:953-957.
[7] Catterall WA, Pedersen PL. Adenosine triphosphatase from rat liver mitochondria.Ⅱ. Interaction with adenosine diphosphate[J]. J Biol Chem, 1972, 247:7969-7976.
[8] Kalish J, Hamdan A. Management of diabetic foot problem[J]. J Vasc Surg, 2010, 51:476-486.
[9] Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis:glycosylated hemoglobin and cardiovascular disease in diabetes mellitus[J]. Ann Intern Med, 2004, 141:421-431.
[10] Gershater MA, Londahl M, Nyberg P, et al. Complexity of factors related to outcome of neuropathic and neuroischaemic/ischaemic diabetic foot ulcers:a cohort study[J]. Diabetologia,2009, 52:398-407.
[11] Apelqvist J. The foot in perspective[J]. Diabetes Metab Res Rev, 2008, 24(Suppl 1):S110-S115.
[12] Apelqvist J, Bakker K, van Houtum WH, et al. International consensus and practical guidelines on the management and the prevention of the diabetic foot. International Working Group on the Diabetic Foot[J]. Diabetes Metab Res Rev, 2000, 16(Suppl 1):S84-S92.
[13] Jeffcoate WJ, Chipchase SY, Ince P, et al. Assessing the outcome of the management of diabetic foot ulcers using ulcerrelated and person-related measures[J]. Diabetes Care, 2006,29:1784-1787.
[14] Clairotte C, Retout S, Potier L, et al. Automated ankle-brachial pressure index measurement by clinical staff for peripheral arterial disease diagnosis in nondiabetic and diabetic patients[J].Diabetes Care, 2009, 32:1231-1236.
[15] Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease(TASCⅡ)[J]. Eur J Vasc Endovasc Surg, 2007, 33(Suppl 1):S1-S75.
[16] European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of HypertensionEuropean Society of Cardiology guidelines for the management of arterial hypertension[J]. J Hypertens, 2003, 21:1011-1153.
[17] American Diabetes Association. Standards of medical care in diabetes-2006[J]. Diabetes Care, 2006, 29(Suppl 1):S4-S42.
[18] Lepantalo M, Apelqvist J, Setacci C, et al. ChapterⅤ:diabetic foot[J]. Eur J Vasc Endovasc Surg, 2011, 42(Suppl 2):S60-S74.
[19] Elraiyah T, Tsapas A, Prutsky G, et al. A systematic review and meta-analysis of adjunctive therapies in diabetic foot ulcers[J]. J Vasc Surg, 2016, 63(2 Suppl):46S.el-2-58S.el-2.
[20] Meloni M, Izzo V, Vainieri E, et al. Management of negative pressure wound therapy in the treatment of diabetic foot ulcers[J]. World J Orthop, 2015, 6:387-393.
[21] Shi R, Jin Y, Cao C, et al. Localization of human adiposederived stem cells and their effect in repair of diabetic foot ulcers in rats[J]. Stem Cell Res Ther, 2016, 7:155.
[22] Lu C, Zhang X, Zhang D, et al. Short time tripterine treatment enhances endothelial progenitor cell function via heat shock protein 32[J]. J Cell Physiol, 2015, 230:1139-1147.
[23] Lu C, Yu X, Zuo K, et al. Tripterine treatment improves endothelial progenitor cell function via integrin-linked kinase[J].Cell Physiol Biochem, 2015, 37:1089-1103.
[24] Zuo K, Li M, Zhang X, et al. MiR-21 suppresses endothelial progenitor cell proliferation by activating the TGFβsignaling pathway via downregulation of WWP1[J]. Int J Clin Exp Pathol,2015, 8:414-422.
[25] Zhang X, Lian W, Lou W, et al. Transcatheter arterial infusion of autologous CD133+cells for diabetic peripheral artery disease[J]. Stem Cells Int, 2016, 2016:6925357.
[26] Zhao WN, Xu SQ, Liang JF, et al. Endothelial progenitor cells from human fetal aorta cure diabetic foot in a rat model[J].Metabolism, 2016, 65:1755-1767.
[27] Wu Q, Chen B, Liang Z. Mesenchymal stem cells as a prospective therapy for the diabetic foot[J]. Stem Cells Int, 2016,2106:4612167.
[28] Hinchliffe RJ, Brownrigg JR, Apelqvist J, et al. IWGDF guidance on the diagnosis, prognosis and management of peripheral artery disease in patients with foot ulcers in diabetes[J]. Diabetes Metab Res Rev, 2016, 32(Suppl 1):37-44.
[29] Asadi MR, Torkaman G, Hedayati M, et al. Angiogenic effects of low-intensity cathodal direct current on ischemic diabetic foot ulcers:a randomized controlled trial[J]. Diabetes Res Clin Pract,2017, 127:147-155.
[30] Chatwin KE, Abbott CA, Reddy PN, et al. A foreign body through the shoe of a person with diabetic peripheral neuropathy alters contralateral biomechanics:captured through innovative plantar pressure technology[J]. Int J Low Extrem Wounds, 2018,17:125-129.
[31] Crisologo PA, Lavery LA. Remote home monitoring to identify and prevent diabetic foot ulceration[J]. Ann Transl Med, 2017,5:430.